COVID-19
Conditions
Keywords
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), Pregnancy, Paxlovid, Nirmatrelvir
Brief summary
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects can be tolerated for treatment of pregnant women with mild or moderate COVID-19 compared to non-pregnant women with mild or moderate COVID-19. This study is seeking participants who: * are expecting a healthy baby and are in their second or third trimester pregnancy and have mild or moderate COVID-19 * are not pregnant and have mild or moderate COVID-19. All participants in this study will take Paxlovid by mouth every 12 hours for 5 days. We will study the experiences of people receiving the study medicine. This will help us decide if the study medicine is safe. All participants will take part in this study for at least 34 days; pregnant participants will take part until their delivery, so that the study duration may be up to 6 months, depending on their delivery date. During this time, participants will have 7to 8 visits and, if pregnant, a visit at delivery. Around 2 to 3 visits and the delivery visit will be done in person (at the clinic or at the participant's home). The other 5 visits may be done over the phone, unless in-person visit is necessary as decided by the doctor. Blood samples will be collected on the first 4 to 5 study visits (and at other study visits, if necessary).
Interventions
DRUGnirmatrelvir
Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
DRUGritonavir
Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
(Open Label)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* All cohorts: Mild-to-moderate COVID-19 infection confirmed in sample collected ≤5 days prior to enrollment; onset within 5 days prior to enrollment and presence of ≥1 sign/symptom on the day of enrollment. * Cohorts 1&2: Expecting single baby; Pregnant in 2nd trimester, 14 0/7 to 27 6/7 weeks of gestational age (Cohort 1) or 3rd trimester, ≥28 0/7 and ≤34 6/7 weeks of gestational age (Cohort 2), by ultrasound. * All cohorts: Otherwise healthy participants who are determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study
Exclusion criteria
* All cohorts: Current need for hospitalization or anticipated need for hospitalization in the clinical opinion of the site investigator. * Cohorts 1&2: Prior/current major condition or illness of mother/fetus substantially increasing risk of study participation/completion or impacting pregnancy/fetal outcomes in investigator's judgement. * All cohorts: Current use of any medications that are highly dependent on CYP3A4 for clearance, and which are contraindicated in combination with nirmatrelvir/ritonavir. * All cohorts: Has received or is expected to receive monoclonal antibody treatment, convalescent COVID-19 plasma, or anti-viral treatment (eg, molnupiravir) for the current SARSCoV-2 infection. * All cohorts: Participants with moderate to severe kidney impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apparent Oral Clearance (CL/F) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Apparent Volume of Distribution (Vz/F) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Maximum Observed Plasma Concentration (Cmax) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Plasma Decay Half-Life (t1/2) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Observed Plasma Trough Concentration (Ctrough) | Day 1: 1-3 hour post-dose; Day 3: 4-8 hour post-dose; Day 4: 8 to less than 12 hour post dose; Day 5: 2-4 hour, 6-8 hour, 10 to less than 12 hour post dose. |
| Incidence of Treatment Emergent Adverse Events (TEAEs) | Baseline up through Day 34 |
| Incidence of TEAEs, SAEs, and AEs leading to discontinuations | Baseline up through end of treatment (Day 5/Day 6) |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with stillbirths | At delivery of the baby |
| Number of participants with spontaneous abortions | At delivery of the baby |
| Number of participants with induced/elective abortions | At delivery of the baby |
| Number of participants with unknown delivery | At delivery of the baby |
| Number of aborted or stillborn fetuses with abnormal findings upon gross visual inspection | At delivery of the baby |
| Number of participants with delivery at medical facility | At delivery of the baby |
| Number of neonates with congenital malformation/anomaly or other neonatal problem | At birth |
| Body weight of newborn infants | At birth |
| Body length of newborn infants | At birth |
| Head circumference of newborn infants | At birth |
| Incidence of SAEs in newborn infants | Birth through 24 hours after birth or until Study Day 34 (whichever is later) |
| Gestational age of newborn infants | At birth |
| Number of participants with delivery at home | At delivery of the baby |
| Number of participants with delivery at other location | At delivery of the baby |
| Number of participants with caesarean section delivery | At delivery of the baby |
| Number of participants with vaginal delivery | At delivery of the baby |
| Number of participants with complications during delivery | At delivery of the baby |
| Number of full-term live deliveries | At delivery of the baby |
| Number of premature live deliveries | At delivery of the baby |
Countries
United States
Outcome results
None listed